Back to top
more

Evofem Biosciences (EVFM)

(Delayed Data from OTC)

$0.01 USD

0.01
178,028

0.00 (-4.70%)

Updated Apr 25, 2024 03:55 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Endo (ENDP) Stock Wilted After its Surge on Tuesday?

by Zacks Equity Research

Endo International (ENDO) tanks 26%, cooling off after its massive stock price surge on Tuesday, post the Supreme Court's decision to overturn Roe v. Wade.

Is the Options Market Predicting a Spike in Evofem Biosciences (EVFM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

Evofem Biosciences (EVFM) Looks Good: Stock Adds 10.1% in Session

by Zacks Equity Research

Evofem Biosciences (EVFM) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

Company News for May 27, 2020

by Zacks Equity Research

Companies In The News Are: EVFM, BNFT, SRNE, CLRB

Are Options Traders Betting on a Big Move in Evofem Biosciences (EVFM) Stock?

by Zacks Equity Research

Investors need to pay close attention to Evofem Biosciences (EVFM) stock based on the movements in the options market lately.

PDL BioPharma (PDLI) Misses on Q4 Earnings, To Dissolve by Year-End

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings lag estimates in the fourth quarter. The company announces plan to complete liquidation by the end of 2020.

PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales

by Zacks Equity Research

PDL BioPharma (PDLI) impresses investors with third-quarter earnings beat. LENSAR laser system bumps up sales as well. However, revenues fall year over year.

PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts

by Zacks Equity Research

PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY

by Zacks Equity Research

A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.

Evofem Shares Up as Birth Control Gel Succeeds in Phase III

by Zacks Equity Research

Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.

3 Small Biotech Stocks That Almost Doubled in Past Month

by Zacks Equity Research

We take a look at three biotech stocks, prices of which have almost doubled in the past month.